SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliance Certificate - Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Pursuant to Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate dated April 28, 2023 issued by M/s. Veenit Pal & Associates, Practicing Company Secretaries, for the year ended March 31, 2023. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to 'Sun Pharma launches CEQUA(r), a novel therapy for Dry Eye Disease in India', which we shall be releasing after sending this letter to you. This submission is being made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sun Pharma's Mohali facility to pause supplies to the US; stock dips 3%
Although the overall impact could be minimal (being an OSD facility), this may lead to stricter scrutiny for other plants, said ICICI Securities in a note. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On Mohali Facility
This is with respect to our prior communications, dated November 8, 2022 and August 13, 2022, regarding the US FDA inspection at the Company's Mohali (Punjab) facility from August 3 to August 12, 2022. As stated earlier, US FDA had classified the inspection as 'Official Action Indicated' (OAI). We now wish to inform you that the Company has received a letter titled 'CONSENT DECREE CORRESPONDENCE/NON-COMPLIANCE LETTER' from the US FDA. US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US. These actions include, among others, retaining an independent CGMP expert to conduct batch certifications of drugs manufactured at the Mohali facility. The Company is taking required corrective steps, but there will be a temporary pause in release of batches from Mohali until US FDA mandated measures are implemented. US shipments from Mohali will resume once these measures are in place. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySUN PHARMACEUTICAL INDUSTRIES LTD. 2CIN NO.L24230GJ1993PLC019050 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Anoop Deshpande Designation: Company Secretary and Compliance Officer EmailId: anoop.deshpande@sunpharma.com Name of the Chief Financial Officer: C S Muralidharan Designation: Chief Financial Officer EmailId: secretarial@sunpharma.com Date: 21/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySUN PHARMACEUTICAL INDUSTRIES LTD. 2CIN NO.L24230GJ1993PLC019050 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Anoop Deshpande Designation: Company Secretary and Compliance Officer EmailId: anoop.deshpande@sunpharma.com Name of the Chief Financial Officer: C S Muralidharan Designation: Chief Financial Officer EmailId: secretarial@sunpharma.com Date: 19/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Regulation 7(3) Certificate
Certificate attached